GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Net Change in Cash

NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) Net Change in Cash : $-127.28 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

NewAmsterdam Pharma Co NV's Net Change in Cash for the six months ended in Dec. 2023 was $-67.48 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-127.28 Mil.

NewAmsterdam Pharma Co NV Net Change in Cash Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Net Change in Cash Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Change in Cash
6.59 50.49 407.60 -127.28

NewAmsterdam Pharma Co NV Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Change in Cash Get a 7-Day Free Trial -21.91 38.01 369.59 -59.80 -67.48

NewAmsterdam Pharma Co NV Net Change in Cash Calculation

NewAmsterdam Pharma Co NV's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-141.218+-0.024+8.912+5.052
=-127.28

NewAmsterdam Pharma Co NV's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-72.904+-5.645+0.193+10.878
=-67.48

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-127.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewAmsterdam Pharma Co NV Net Change in Cash Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Net Change in Cash
Comparable Companies
MDXG VERV AKRO ADMA ICPT SLNO INVA OLMA NVAX COGT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
KH6:Germany
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
Website
https://www.newamsterdampharma.com
NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) Headlines

From GuruFocus

NewAmsterdam Pharma Announces Appointment of William �BJ� Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

By Marketwired • 08-14-2023

NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer

By Value_Insider Value_Insider • 12-19-2022

NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares

By sperokesalga sperokesalga • 06-07-2023

NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023

By sperokesalga sperokesalga • 06-03-2023

NewAmsterdam Pharma to Present at Jefferies Healthcare Conference

By sperokesalga sperokesalga • 05-31-2023

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an ApoE4 Mutation

By Marketwired • 09-21-2023

NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy

By Stock market mentor Stock market mentor • 01-17-2023

NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors

By Stock market mentor Stock market mentor • 02-06-2023

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

By Marketwired • 10-23-2023

NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares

By GlobeNewswire GlobeNewswire • 06-07-2023